Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.0800+0.1800 (+4.62%)
At close: 04:00PM EDT
4.1483 +0.07 (+1.67%)
After hours: 07:28PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-160,928
-160,928
-281,721
-212,151
-173,387
Depreciation & amortisation
18,282
18,282
13,758
5,850
3,087
Stock-based compensation
43,459
43,459
78,733
54,364
30,753
Change in working capital
19,182
19,182
-34,710
2,098
-12,773
Accounts receivable
36,654
36,654
-29,804
-3,160
-5,515
Other working capital
-138,416
-138,416
-283,774
-213,574
-44,161
Other non-cash items
-40,860
-40,860
-24,012
-18,098
111,415
Net cash provided by operating activities
-132,263
-132,263
-248,208
-162,870
-39,229
Cash flows from investing activities
Investments in property, plant and equipment
-6,153
-6,153
-35,566
-50,704
-4,932
Purchases of investments
-358,810
-358,810
-404,796
-968,159
-277,344
Sales/maturities of investments
477,628
477,628
607,113
694,840
121,200
Net cash used for investing activities
112,665
112,665
166,751
-324,023
-161,076
Cash flows from financing activities
Debt repayment
-
-
-
0
0
Common stock issued
-
-
0
411,735
272,693
Other financing activities
-
-
-
-
490
Net cash used provided by (used for) financing activities
85
85
9,207
453,129
282,838
Net change in cash
-19,513
-19,513
-72,250
-33,764
82,533
Cash at beginning of period
76,560
76,560
148,810
182,574
100,041
Cash at end of period
57,047
57,047
76,560
148,810
182,574
Free cash flow
Operating cash flow
-132,263
-132,263
-248,208
-162,870
-39,229
Capital expenditure
-6,153
-6,153
-35,566
-50,704
-4,932
Free cash flow
-138,416
-138,416
-283,774
-213,574
-44,161